These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37259485)
21. A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators. Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E J Clin Pharm Ther; 2021 Apr; 46(2):286-294. PubMed ID: 33285018 [TBL] [Abstract][Full Text] [Related]
22. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
23. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. McColley SA Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005 [TBL] [Abstract][Full Text] [Related]
24. Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Hoy SM Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874 [TBL] [Abstract][Full Text] [Related]
25. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE; J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799 [TBL] [Abstract][Full Text] [Related]
26. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C; Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738 [No Abstract] [Full Text] [Related]
27. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease? Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
29. Tezacaftor for the treatment of cystic fibrosis. Sala MA; Jain M Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878 [TBL] [Abstract][Full Text] [Related]
30. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636 [TBL] [Abstract][Full Text] [Related]
31. Entering the era of highly effective modulator therapies. Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412 [TBL] [Abstract][Full Text] [Related]
32. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431 [TBL] [Abstract][Full Text] [Related]
33. Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review. Hansen CME; Breukelman AJ; van den Bemt PMLA; Zwitserloot AM; van Dijk L; van Boven JFM Eur Respir Rev; 2024 Jul; 33(173):. PubMed ID: 39142708 [TBL] [Abstract][Full Text] [Related]
34. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208 [TBL] [Abstract][Full Text] [Related]
35. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis. Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870 [TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE; Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080 [TBL] [Abstract][Full Text] [Related]